Abbott Labs/ALZA acquisition
This article was originally published in The Tan Sheet
Executive Summary
Abbott is purchasing ALZA Corp. in a stock-for-stock merger transaction valued at $7.3 bil., the companies announce June 21. Palo Alto, Calif.-based ALZA specializes in developing drug delivery systems including the technology for the Nicoderm CQ transdermal patch, licensed by SmithKline Beecham, and a 24-hour time release osmotic technology used in various OTC cough/cold remedies. Abbott intends to account for the transaction as a pooling of interests. The deal is expected to be completed by year-end
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning